Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹983.10
₹23.00(2.25%)
At close: 4:00 PM EDT
₹983.10
₹23.00(2.25%)
Day’s Range― - ―
52-Week Range₹769.60 - ₹1,260.10
Previous CloseN/A
Volume248.70K
Average Volume (3M)13.35K
Market Cap
₹100.76B
Enterprise Value₹102.30B
Total Cash (Recent Filing)₹2.13B
Total Debt (Recent Filing)₹17.58B
Price to Earnings (P/E)15.5
Beta0.93
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)60.35
Shares Outstanding92,172,714
10 Day Avg. Volume11,279
30 Day Avg. Volume13,348
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68.3
Revenue Forecast (FY)₹56.72B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability RecoverySteady revenue growth combined with a move from losses to solid profitability indicates improving commercial execution and earnings power. The stronger 2026 margin provides a more durable base for reinvestment, product launches, and resilience across future reporting periods.
Improved Leverage And ReturnsMaterial deleveraging and a recovery in returns strengthen financial flexibility compared with the highly leveraged and loss-making period. Lower relative debt can support continued investment in pharmaceutical products while reducing balance-sheet pressure as profitability improves.
Broad Pharmaceutical PlatformA portfolio spanning generic and specialty products, several dosage forms, and both regulated and emerging markets gives Strides multiple routes to commercialize medicines. Its own registrations and partner channels can broaden market access and support recurring product sales.
Bears Say
Weak Free-Cash-Flow ConversionWeak and volatile free-cash-flow conversion reduces the quality of reported earnings and can constrain internally funded investment. The sharp 2026 decline, together with earlier negative free cash flow, suggests that profits may not consistently translate into usable cash.
Meaningful Remaining DebtAlthough leverage has improved, meaningful absolute debt still limits financial flexibility relative to a stronger balance sheet. Because the company only recently exited stressed profitability, debt obligations could remain a constraint on capital allocation during weaker operating periods.
Generic Pricing And Tender ExposureDependence on competition, tender outcomes, and channel mix can make revenue and margins less predictable even when product volumes remain healthy. This structural exposure may limit pricing power and make sustained profitability harder across generic pharmaceutical markets.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹769.60 and its highest was ₹1260.10 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹100.76B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is Oct 29, 2026 which is today.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on Jul 31, 2026. The company reported ₹17 earnings per share for the quarter.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹17 in its last earnings report. Following the earnings report the stock price went down -4.226%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Piramal Pharma Limited
―
Sun Pharmaceutical Industries Limited
―